Figure 1.

Iron oxide MNPs combined with AT augmented cell-proliferation suppression in NSCLC cells.

Notes: (A) Chemical structure of AT. (B) Representative image of Fe₃O₄ MNPs via transmission electron microscopy. (C) Size distribution histogram of prepared Fe₃O₄ MNPs. (D) Cell viability of NSCLC cells of A549 and H1975 and human normal lung epithelial cells of BEAS2B after treatment with AT (concentrations of 0, 1, 2.5, 5, 10, 15, 20, 25, and 30 μM) and AT-MNP (MNP concentration of 20 μg/mL) combination for 24 hours. (E) Cell viability of NSCLC cells of A549 and H1975 and human normal lung epithelial cells of BEAS2B after treatment with MNPs (MNP concentrations of 0, 2.5, 5, 10, 15, 20, 25, 30, and 40 μg/mL) and AT-MNP (20 μM) combination for 24 hours. Values are expressed as means ± standard error of mean. *P<0.05, **P<0.01, and ***P<0.001 vs Con group of AT-MNP combination; ^#P<0.05, ^##P<0.01, and ^###P<0.001 vs Con group of MNP or AT monotherapy.

Abbreviations: MNPs, magnetic nanoparticles; AT, actein; NSCLC, non-small-cell lung cancer; Con, control; NS, not significant.